---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-25-000045"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T12:52:16.231349+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech Q1 VYJUVEK revenue $88.2M; net income $35.7M; EU approval secured

## Summary
- VYJUVEK net product revenue $88.2M in Q1 2025 (vs $45.3M Q1 2024); gross margin 94%.
- Net income $35.7M ($1.24 basic EPS) vs $0.9M ($0.03) year ago; cash $765.3M.
- European Commission approved VYJUVEK for DEB; first Germany launch mid-2025; Japan decision expected 2H2025.
- Second ophthalmic program KB801 IND cleared for neurotrophic keratitis; Phase 1/2 EMERALD-1 starts May 2025.
- FY2025 non-GAAP R&D+SG&A guidance $150-175M; upcoming readouts for CF, AATD, ocular DEB, aesthetics.

## SEC filing metadata
- accession: 0001711279-25-000045
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127925000045/0001711279-25-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127925000045/krys-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-25-000045
- JSON: https://secwatch.observer/filing/0001711279-25-000045.json
- Plain text: https://secwatch.observer/filing/0001711279-25-000045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.